Merck Presents Results from P-IIa Clinical Trial of Islatravir (MK-8591) for the Prevention of HIV at IAS 2021

Shots:

  • The ongoing P-IIa trial evaluating the safety, tolerability & PK of islatravir (60/120mg, PO, once-monthly for 6 mos.) vs PBO in a ratio (2:2:1) in 242 patients with PrEP of HIV infection for 24 wks.
  • The PK analysis showed that the level of islatravir (60/120 mg monthly doses) in PBMCs continues to remain above the pre-specified PK threshold for PrEP & sustained through 8 wks. after a last dose of islatravir. The therapy was generally well tolerated with no serious AEs
  • Islatravir is currently being evaluated across a variety of dosing regimens as monothx & in combination with other antiretrovirals for the prevention of HIV including two P-III IMPOWER trials

Click here to­ read full press release/ article | Ref: Merck | Image: Spagnola & Associates

The post Merck Presents Results from P-IIa Clinical Trial of Islatravir (MK-8591) for the Prevention of HIV at IAS 2021 first appeared on PharmaShots.